Shen Ching-Hsiung, Cho Yu-Jen, Lin Yi-Ching, Chien Li-Chin, Lee Tzer-Min, Chuang Wen-Hsi, Lin Jui-Che
Department of Chemical Engineering, National Cheng Kung University, Tainan, 70101, Taiwan.
J Mater Sci Mater Med. 2015 Feb;26(2):79. doi: 10.1007/s10856-015-5420-8. Epub 2015 Jan 29.
Despite of its widely uses in various clinical applications, the titanium-based material still faces different challenges, such as hemocompatibility and anti-biofouling characteristics required in various situations. The objective of this investigation was to develop a novel surface modification strategy for titanium-based material to improve the platelet compatibility that is important in rigorous blood-contacting cardiovascular applications. In this work, a series of copolymers, which composed of novel 6-acryloyloxy hexyl phosphonic acid (AcrHPA) and sulfobetaine methacrylate (SBMA) was synthesized. The phosphonic acid group in these copolymers can impart covalent binding to the titanium substrate while the zwitterionic sulfobetaine functionality is considered being able to reduce the platelet adhesion and activation on the modified titanium substrate. NMR analyses suggested that copolymerization reaction is likely not an ideal statistical reaction but to add the monomers in a random order. Studies have shown that the composition of the monomers affected the surface characteristics and platelet compatibility of these covalent-bound AcrHPA-SBMA copolymers on titanium substrate. Contact angle analysis has shown the addition of SBMA can increase surface hydrophilicity of the spun-coated copolymers. In addition, AFM analyses have revealed that the surface roughness of the spun-coated copolymer layer were varied with the ratio of AcrHPA and SBMA. The most platelet compatible surface was noted on the one modified by the highest amount of SBMA added (i.e. 70 mol%) in copolymerization. In summary, the surface modification scheme presented here would be of potential as well as manufacturing process applicable for future development in blood-contacting titanium-based biomedical devices.
尽管钛基材料在各种临床应用中得到了广泛使用,但它仍然面临着不同的挑战,例如在各种情况下所需的血液相容性和抗生物污损特性。本研究的目的是开发一种用于钛基材料的新型表面改性策略,以改善血小板相容性,这在严格的血液接触心血管应用中很重要。在这项工作中,合成了一系列由新型6-丙烯酰氧基己基膦酸(AcrHPA)和甲基丙烯酸磺酸甜菜碱(SBMA)组成的共聚物。这些共聚物中的膦酸基团可以与钛基底形成共价结合,而两性离子磺酸甜菜碱官能团被认为能够减少血小板在改性钛基底上的粘附和活化。核磁共振分析表明,共聚反应可能不是理想的统计反应,而是以随机顺序添加单体。研究表明,单体的组成影响了这些共价结合的AcrHPA-SBMA共聚物在钛基底上的表面特性和血小板相容性。接触角分析表明,添加SBMA可以增加旋涂共聚物的表面亲水性。此外,原子力显微镜分析表明,旋涂共聚物层的表面粗糙度随AcrHPA和SBMA的比例而变化。在共聚过程中添加最高量SBMA(即70摩尔%)改性的表面具有最适合血小板的性能。总之,本文提出的表面改性方案以及制造工艺对于未来血液接触钛基生物医学装置的发展具有潜在的应用价值。